Merit E. Cudkowicz MGH-Takeda Neuroscience Fellowship
Andrew J. Cole, MD, FRCP
Neurological Clinical Research Fellowships, Massachusetts General Hospital
Martin M. Bednar, MD, PhD, FAANS
VP, Neuroscience and Takeda Fellowship Director
Takeda Pharmaceuticals International Co.
This fellowship provides a unique opportunity for a board-certified or board-eligible physician scientist trained in Neurology to spend 50% of their time within the two-year Fellowship working with the Takeda Neuroscience Therapeutic Area Unit in Cambridge, MA, while performing clinical activities at Massachusetts General Hospital in Boston. The recipient of this Fellowship will have an opportunity to work on one of a number of diverse projects that constitute a rich pipeline of new molecular entities for neurologic diseases.
The Fellow will also receive formal training in translational medicine, clinical trial design and general pharmaceutical industry drug development and leadership training. Prior experience in drug development/translational research is not required.
The clinician-scientists are selected by a joint Takeda-Mass General Search Committee and employed by Mass General. There is a 50% protected time commitment to Takeda Neuroscience and a 50% commitment to clinical and/or research activities at Mass General within the Department of Neurology. The program provides annual salary support plus benefits. Appointment begins on July 1, 2023.
Physician scientist who is or will be a BC/BE Neurologist by July 1, 2023
Fellow or Junior faculty in Neurology
Ability to commit 50% of time to Takeda and 50% of time to MGH
How to ApplyDownload application form
Applicants should submit the application as a single PDF file to Program Coordinator Joanna Richards. Applications must include:
- Letter of intent (2 pages maximum) describing the relevance of this program to previous experience, research interests and career goals
Current Curriculum Vitae (CV)
Two letters of support
NIH Other Support – current and pending grants
Application must be submitted by November 1, 2022 for consideration